The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 13, 2024

Filed:

Apr. 14, 2021
Applicant:

Genzyme Corporation, Cambridge, MA (US);

Inventors:

Elyse Bourque, Blaine, WA (US);

Mario A. Cabrera-Salazar, Brighton, MA (US);

Cassandra Celatka, Hull, MA (US);

Seng H. Cheng, Natick, MA (US);

Bradford Hirth, Littleton, MA (US);

Andrew Good, Wallingford, CT (US);

Katherine Jancsics, Wilmington, MA (US);

John Marshall, Charlestown, MA (US);

Markus Metz, Encinitas, CA (US);

Ronald K. Scheule, Hopkinton, MA (US);

Renato Skerlj, W. Newton, MA (US);

Yibin Xiang, Dracut, MA (US);

Zhong Zhao, Wayland, MA (US);

John Leonard, Manchester, NH (US);

Thomas Natoli, Revere, MA (US);

Elina Makino, Winchester, MA (US);

Herve Husson, Boston, MA (US);

Oxana Beskrovnaya, Southborough, MA (US);

Assignee:

GENZYME CORPORATION, Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 453/02 (2006.01); A61K 31/439 (2006.01); A61K 31/496 (2006.01); A61K 31/497 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/55 (2006.01); A61K 31/551 (2006.01); A61K 45/06 (2006.01); C07D 471/08 (2006.01);
U.S. Cl.
CPC ...
C07D 453/02 (2013.01); A61K 31/439 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); A61K 45/06 (2013.01); C07D 471/08 (2013.01);
Abstract

The invention relates to inhibitors of glucosylceramide synthase (GCS) of the Formula I: represented by the following structural formula or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein, useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.


Find Patent Forward Citations

Loading…